BioSpace

Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy

Novartis remains "very happy" with its $12 billion acquisition of Avidity Biosciences, despite a Phase 3 disappointment for the antibody-oligonucleotide conjugate del-desiran.

By BioSpace

1 min read
Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights